Alliance For Clinical Trials In Oncology

This study tests whether adding a chemotherapy drug (docetaxel) to the usual hormone therapy plus apalutamide helps men with prostate cancer that has spread to other parts of the body live longer. About 1,260 participants will receive either the standard two-drug treatment or the…

This study is for people with early-stage HER2-positive breast cancer whose tumors completely disappeared after initial chemotherapy and HER2-blocking drugs. It compares 6 months of continued HER2-targeted therapy versus the standard 12 months, to see if the shorter course is jus…

This study tests a tool called PAGODA that helps doctors adjust chemotherapy doses ahead of time to avoid unplanned treatment delays. About 420 people with cancers of the digestive system (like colon, stomach, or esophageal cancer) will take part. The goal is to see if using this…

This study is for people with colorectal cancer that has spread to up to 4 places in the body. It compares standard drug therapy alone versus standard therapy plus targeted treatments like precise radiation, surgery, or heat ablation to destroy those cancer spots. The goal is to …

This study tests whether a text-message program can help rural cancer survivors who smoke at least 5 cigarettes a day to quit. Participants will either get the text program or a printed manual. The main goal is to see if more people in the text group have stopped smoking after 6 …

This study tests whether adding tivozanib to the standard immunotherapy pembrolizumab can better prevent high-risk kidney cancer from returning after surgery. About 1,040 adults with clear cell renal cell carcinoma at intermediate-high or high risk will be randomly assigned to ge…

This study tests four targeted drugs (vismodegib, GSK2256098, capivasertib, and abemaciclib) in people with progressive meningiomas that have specific gene mutations. The goal is to see if these drugs can stop or slow tumor growth. About 124 adults with recurrent or worsening men…

This study is for people with a rare and aggressive type of mesothelioma called sarcomatoid. It tests whether giving two immunotherapy drugs (nivolumab and ipilimumab) before surgery can help control the cancer better than surgery alone. About 26 participants will receive the dru…

This study looks at whether giving chemotherapy and immunotherapy both before and after surgery is better than giving it only after surgery for people with stage II to IIIB non-small cell lung cancer that can be removed. About 1,100 adults will be randomly assigned to one of the …

This phase 3 trial tests whether adding the chemotherapy drug gemcitabine to standard BCG immunotherapy can better prevent bladder cancer from coming back. About 330 people with recurrent high-grade non-muscle invasive bladder cancer will receive either BCG alone or BCG plus gemc…

This study tests whether adding a targeted drug called inotuzumab ozogamicin to standard chemotherapy helps young adults (ages 18-39) with a type of blood cancer called B-cell acute lymphoblastic leukemia. The drug works like a smart bomb, seeking out and killing cancer cells whi…

This study looks at whether older patients with mantle cell lymphoma can safely stop taking zanubrutinib after their cancer goes into remission, and only restart it if the cancer returns. Currently, patients take this drug every day indefinitely, which can be costly and cause sid…

This study is for people with early-stage triple-negative breast cancer who had a complete response (no cancer left) after chemotherapy plus the immunotherapy drug pembrolizumab. The trial compares receiving more pembrolizumab versus simply being watched (observation) to see if t…

This study compares two chemotherapy combinations for people with advanced stomach, esophageal, or gastroesophageal junction cancer that cannot be removed by surgery. About 382 participants will receive either the standard FOLFOX chemo (with or without the immunotherapy nivolumab…

This study tests whether adding a drug called iberdomide to a standard treatment (belantamab mafodotin plus dexamethasone) is safe and works better for people with multiple myeloma that has come back or stopped responding to prior therapies. About 88 adults will take part. The go…

This study tests a vaginal laser treatment for breast cancer survivors who have vaginal dryness, often caused by cancer treatments like chemotherapy or hormone therapy. About 250 women who finished their main cancer treatment at least a year ago will receive either the laser or a…

This study tests whether a high dose of gabapentin, a nerve pain medication, can prevent the need for opioid painkillers in people with head and neck cancer who develop painful mouth sores from chemotherapy and radiation. About 228 adults with squamous cell carcinoma of the head …

This study tests whether cancer patients can do a supervised exercise program from home using video calls. The goal is to see if it's practical and helps prevent side effects like fatigue and weakness. About 104 adults starting chemotherapy will participate, doing resistance and …

This study is for men with advanced prostate cancer that no longer responds to hormone therapy. Researchers want to see if using genetic tests on tumor tissue can help pick the most effective treatment from several options, including newer targeted drugs and chemotherapy. About 4…

This study collects blood and tissue samples from 2000 people—some with cancer, some without—to help researchers develop and improve blood tests that can detect many types of cancer early. Participants provide samples that are stored and later used to test new diagnostic methods.…

This study is creating a national collection of blood, tissue, and medical information from 240 cancer patients who have experienced serious side effects from immunotherapy. The goal is to store these samples for future research, so scientists can better understand why these side…

This study compares a digital chatbot to standard remote genetic services for increasing genetic counseling and testing among young adults (ages 18-39) with cancer. About 535 participants will be randomly assigned to either the chatbot or standard care. The goal is to see if the …